Table 1.
The relationship between ENO1 status and clinicopathological features of HCC
| Clinicopathological features | Number of cases (n) | ENO1 mRNA expression, n (%)
|
P-value | |
|---|---|---|---|---|
| High | Low | |||
|
| ||||
| Age (years) | ||||
| < Median | 161 | 78 (48.4) | 83 (51.6) | 0.618 |
| > Median | 166 | 85 (51.2) | 81 (48.8) | |
| Race | ||||
| Yellow | 167 | 85 (50.9) | 82 (49.1) | 0.698 |
| White | 160 | 78 (48.7) | 82 (51.3) | |
| Gender | ||||
| Male | 223 | 108 (48.4) | 115 (51.6) | 0.453 |
| Female | 104 | 55 (52.9) | 49 (47.1) | |
| AFP (ng/mL) | ||||
| <20 | 232 | 109 (47.0) | 123 (53.0) | 0.105 |
| >20 | 95 | 54 (56.8) | 41 (43.2) | |
| TNM stage | ||||
| Stage I–II | 244 | 113 (46.3) | 131 (53.7) | 0.023* |
| Stage III–IV | 83 | 50 (60.2) | 33 (39.8) | |
| Histological type | ||||
| HCC | 317 | 157 (49.5) | 160 (50.5) | 0.514 |
| Non-HCC | 10 | 6 (60.0) | 4 (40.0) | |
| Differentiation grade | ||||
| Grade 1–2 | 202 | 89 (44.1) | 113 (55.9) | 0.008** |
| Grade 3–4 | 125 | 74 (59.2) | 51 (40.8) | |
Notes:
*
P<0.05.
**
P<0.01.
Abbreviations: AFP, α-fetoprotein; ENO1, enolase-1; HCC, hepatocellular carcinoma.